



Express Mail No. EV335856613US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

38/Suppl Prior
Art Unit
RECEIVED
AUG 14 2003
TECH CENTER 1600/2900

Application of: Zou et al.

Confirmation No.: 4389

Application No.: 09/122,427

Group Art Unit: 1615

Filed: July 24, 1998

Examiner: Gollamudi S. Kishore

For: SUBMICRON LIPOSOME SUSPENSIONS
OBTAINED FROM PRELIPOSOME
LYOPHILATES

Attorney Docket No.: 8449-238
(Previously UTSC584USC2)

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.56 AND § 1.97**

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to the references C2-C16 listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant." Copies of references C2-C16 are submitted herewith.

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Applicants also wish to direct the Examiner's attention to errors noted in the Information Disclosure Statement filed on July 24, 1998 in connection with the above-identified application. Specifically, the publication dates for References B6 (JP6293615), B7 (JP6227966) and B8 (JP6183953) are incorrectly listed as August 25, 1992, January 29, 1993, and June 24, 1991, respectively. The correct publication dates for references B6-B8 are October 21, 1994, August 16, 1994, and July 5, 1994, respectively.

Pursuant to 37 C.F.R. § 1.97(b), since this Information Disclosure Statement is being filed concurrently with a Request For Continued Examination (RCE) Transmittal, Applicants believe that no fee is due in connection with the filing of this Information Disclosure Statement. However, should the U.S. Patent and Trademark Office determine otherwise, please charge the required fee to Pennie & Edmonds Deposit Account No. 16-1150. A duplicate of this sheet is enclosed for accounting purposes.

Date August 8, 2003

Respectfully submitted,

Adriane M. Antler
By Geraldine Laro

Adriane M. Antler

(Reg. No.)

PENNIE & EDMONDS LLP

1155 Avenue of the Americas

New York, New York 10036-2711

(212) 790-9090

Reg No
31232
32,605

Enclosures

AUG 14 2003


Express Mail No. EV335856613US

Sheet 1 of 1

TECH CENTER 1600/2900

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)



ATTY DOCKET NO. 8449-238

APPLICATION NO. 09/122,427

APPLICANT Zou et al.

FILING DATE July 24, 1998

GROUP 1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C2	Han et al., Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells. Cancer Res. 53:4913-9, 1993
C3	Hollis et al., cis-diamineplatinum (II) complexes containing phosphono carboxylate ligands as antitumor agents. J Med Chem. 33:105-11, 1990.
C4	Khokhar et al., Chemical and biological studies on a series of lipid-soluble (trans-(R,R)- and -(S,S)-1,2-Diaminocyclohexane)platinum(II) Complexes Incorporated in Liposomes. J. Med. Chem. 34:325-329, 1991
C5	Perez-Soler et al., Lipophilic cisplatin analogues entrapped in liposomes: role of intraliposomal drug activation in biological activity. Cancer Res. 52:6341-7, 1992.
C6	Perez-Soler et al., Increased cytotoxicity and reversal of resistance to cis-diamminedichloro-platinum(II) with entrapment of cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) in multilamellar lipid vesicles. Cancer Res. 48:4509-12, 1988.
C7	Perez-Soler et al., Clinical development of Liposomal Platinum. J Lip Res. 1:437-449, 1990
C8	Perez-Soler et al., Lipophilic platinum complexes entrapped in liposomes: improved stability and preserved antitumor activity with complexes containing linear alkyl carboxylate leaving groups. Cancer Chemother Pharmacol. 33:378-84, 1994.
C9	Qu et al., Effect of diamine linker on the chemistry of Bis(Platinum) complexes. A comparison of the Aqueous solution behavior of 1,4-butanediamine and 2,5-dimethyl-2,5-Hexanediamine Complexes. J. Inorganic Biochem. 40:255-264, 1990.
C10	Qu et al., Interaction of bis(platinum) complexes with the mononucleotide 5'-guanosine monophosphate. Effect of diamine linker and the nature of the bis(platinum) complex of product formation. J. Am. Chem. Soc. 113:4851-4857, 1991
C11	Slavin et al., Phosphonato complexes of platinum(II): kinetics of formation and phosphorus-31 NMR characterization studies. J Inorg Biochem. 40(4):339-47, 1990.
C12	Zou et al., Enhanced therapeutic effect against liver W256 carcinosarcoma with temperature-sensitive liposomal adriamycin administered into the hepatic artery. Cancer Res. 53:3046-51, 1993.
C13	Zou et al., Effect of vesicle size and lipid composition on the in vivo tumor selectivity and toxicity of the non-cross-resistant anthracycline annamycin incorporated in liposomes. Int J Cancer. 61:666-71, 1995.
C14	Griffin, WC, Calculation of HLB values of non-ionic surfactants. J Soc Cosmet Chem. 5:249-56, 1954.
C15	Shinoda et al., "Concept of Hydrophile-Lipophile Balance, HLB, of Surfactant" in Emulsions and Solubilization, John Wiley and Sons, New York, NY (1986).
C16	Borisov et al., "Stabilization of Colloidal Dispersions by Grafted Polymers" in Stealth Liposomes, Eds. D. Lasic and F. Martin, CRC press, New York, NY (1995).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.